Alzheimer's Disease

Biogen Inc. and Neomorph Inc. have announced a partnership geared toward research and development of molecular glue degraders to address protein accumulation related to Alzheimer’s disease and other neurologic conditions.

Plasma pTau181 in combination with ApoE4 assays registered a high degree of accuracy in ruling out patients with a low probability of amyloid pathology in the early stages of Alzheimer’s disease, according to a poster presentation at CTAD.

The International Working Group has updated diagnostic guidelines for Alzheimer’s disease to include individuals with normal cognition who test positive for core biomarkers indicative of disease pathology.

Treatment with non-invasive, personalized repetitive transcranial magnetic stimulation in those with mild to moderate Alzheimer’s resulted in a 44% slowing of disease progression at 52 weeks, according to the manufacturer.

ADx NeuroSciences and Alamar Biosciences have announced a partnership to develop customized biomarker assays for companies that advance novel therapeutics for a range of neurological conditions.

A new guideline on primary prevention of a first stroke from the American Heart Association and the American Stroke Association calls for increased screening of risk factors and increased attention on lifestyle counseling.

In patients with type 2 diabetes, semaglutide was associated with a significantly lower risk for an Alzheimer’s disease diagnosis within 3 years compared with other diabetes medications, according to a study published in Alzheimer’s & Dementia.

BOSTON — In this Healio video exclusive, Virend K. Somers, MD, PhD, discusses his presentation at the Cardiometabolic Health Congress, “Sleep Disorders and Cardiometabolic Health.”

A genetic analysis of postmortem brains from individuals in various stages of Alzheimer’s disease revealed two distinct phases of cell deterioration, according to research published in Nature Neuroscience.

Results from a clinical trial examining intracranial stimulation using a novel device in those with mild Alzheimer’s disease showed that treatment led to improvements in memory, cognitive function and blood flow.